RARE DISEASERESEARCH ATLAS

ORPHA:139426

Perioral myoclonia with absences

medium confidenceDisorder

Also known as: POMA

Publications

32

27.5th percentile

Trials

0

Interventional, condition-specific

Researchers

103

Distinct authors in sample

Gene link

Readiness

1/6

Stages with a signal

Clinical definition (Orphanet)

A rare syndrome characterized by absence with perioral myoclonia as the main seizure type, accompanied by generalized tonic-clonic , appearing before or together with absences. Consciousness is usually impaired, although to variable degree. Commonly observed absence status epilepticus, poor response to antiepileptic drugs and persistence of into adulthood, in the presence of normal neurological status and intelligence, are additional clinical features of this syndrome.

How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

1/6 stages with a signal

Research-stage checklist from open sources (GenCC, literature, Monarch when enriched, ClinicalTrials.gov). Not a prognosis or care recommendation.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    32 matched papers (10 in last 10 years) Source

  3. Phenotype characterisedNot checked

    Not yet enriched from Monarch / HPO

  4. Animal modelNot checked

    Not yet enriched from Monarch / Alliance

  5. Orphan designationNot checked

    FDA/EMA orphan-drug designation not enriched yet

  6. Interventional trialNot found

    No matched interventional trial under our ClinicalTrials.gov rules

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

Not enriched in this build — Monarch phenotype joins were not run for this record.

Animal models (Monarch / Alliance)

Not enriched in this build.

Literature

Is anyone studying this?

32

32 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.

32 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).

10 in the last 10 years · medium confidence · 27.5th percentile (publications denominator)

Phrase hits: 32 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

103

Distinct author names in 32 sampled papers — named people below.

Who's working on it?

No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.

  1. 01
    Panayiotopoulos CP6 papers · 2005

    Department of Clinical Neurophysiology and Epilepsies, St Thomas' Hospital, London SE1 7EH, UK.

    Papers in Europe PMC
  2. 02
    Agathonikou A3 papers · 1998

    Department of Clinical Neurophysiology and Epilepsies, St. Thomas' Hospital, London, England.

    Papers in Europe PMC
  3. 03
    Baykan B2 papers · 2005

    University of Istanbul, Istanbul Faculty of Medicine, Department of Neurology, Istanbul, Turkey. baykankurtg@superonline.com.tr

    Papers in Europe PMC
  4. 04
    Giannakodimos S2 papers · 1998
    Papers in Europe PMC
  5. 05
    Koutroumanidis M2 papers · 1998
    Papers in Europe PMC
  6. 06
    Adams SJ1 paper · 2016

    College of Medicine, University of Saskatchewan, Saskatoon, SK, Canada.

    Papers in Europe PMC
  7. 07
    Almubarak S1 paper · 2016

    Division of Pediatric Neurology, Department of Pediatrics, University of Saskatchewan, Saskatoon, SK, Canada.

    Papers in Europe PMC
  8. 08
    Aneja S1 paper · 2013
    Papers in Europe PMC
  9. 09
    Barone FA1 paper · 2022

    Epilepsy Unit, Department of Human Neurosciences, Policlinico "Umberto I", Sapienza University, Rome, Italy.

    Papers in Europe PMC
  10. 10
    Basnyat P1 paper · 2022

    Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

0

interventional trials for this specific condition

No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).

Data as of 27 July 2026

No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.

medium confidence · 36.5th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.

See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.

Where to find support

We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Perioral myoclonia with absences"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Perioral myoclonia with absences"

Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Synonyms dropped by stoplist: POMA

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • 1 synonym(s) dropped by stoplist (may under-count)
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-27T07:35:30.851Z